With respect to PTGS2/COX-2, Jiang et al. indicated that PTGS2/COX-2 might promote cisplatin resistance in NSCLC by favoring epithelial-mesenchymal transition through activation of the AKT signaling pathway [75]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.